Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

摘要: EGFR mutations identify patients who are more likely to respond treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) than cytotoxic chemotherapy. The distinct success of the first-generation TKIs erlotinib and gefitinib has been accompanied by observation that acquired resistance these treatments develops after a median 1 year treatment. Newer, second-generation have developed intent delay or overcome broader inhibition kinases (eg, HER2 vascular endothelial receptor) and/or altering interactions through irreversibly binding domain. This article discusses many agents (including afatinib, dacomitinib, XL647, AP26113, CO-1686) which potential for greater efficacy compared TKIs, may also clinical activity against other oncogenic within family, including HER2.